Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

5,058 studies for “Novartis”

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.Not Yet Recruiting
NCT05776927Phase 3Updated Jul 27, 2026
Sponsor: Novartis Pharmaceuticals
Asthma
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid TumorsRecruiting
NCT07660055Phase 1Updated Jul 27, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer · Non-small Cell Lung Cancer (NSCLC) · Gastric/Gastroesophageal Junction (GEJ) Cancer · Bladder Cancer
Australia, Canada, Japan
A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in GermanyRecruiting
NCT07549516N/AUpdated Jul 27, 2026
Sponsor: Novartis Pharmaceuticals
Leukemia, Chronic Myeloid
Germany
Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine ACompleted
NCT02328963Phase 4Updated Jul 27, 2026
Sponsor: University Hospital, Bordeaux
Transplantation Infection · Cytomegalovirus Infection
France
Phase II Study of BKM120 for Subjects With Recurrent GlioblastomaCompleted
NCT01339052Phase 2Updated Jul 27, 2026
Sponsor: L. Nicolas Gonzalez Castro, MD, PhD
Glioblastoma
United States
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.Recruiting
NCT06632600Phase 2Updated Jul 27, 2026
Sponsor: Novartis Pharmaceuticals
Chagas Disease
United States, Argentina, Brazil, Colombia
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruiting
NCT07354074Phase 2Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Myelogenous Leukemia · Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
United States, Australia, Canada, China, France +6 more
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus ErythematosusActive Not Recruiting
NCT05798117Phase 1, Phase 2Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Systemic Lupus Erythematosus · Lupus Nephritis
Australia, France, Germany, Spain, Switzerland
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)Recruiting
NCT06439082Phase 3Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Sickle Cell Disease
United States, Brazil, Colombia, Kenya, Uganda
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic AnemiaActive Not Recruiting
NCT05648968Phase 3Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Warm Autoimmune Hemolytic Anemia (wAIHA)
United States, Argentina, Australia, China, France +11 more
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCRecruiting
NCT06855277Phase 3Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Prostate Cancer
United States, Australia, Brazil, China, Hong Kong +6 more
A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With EltrombopagRecruiting
NCT07587723N/AUpdated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Immune Thrombocytopenia
Switzerland
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)Active Not Recruiting
NCT05624749Phase 3Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Systemic Lupus Erythematosus
United States, Argentina, Australia, Chile, Colombia +10 more
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)Active Not Recruiting
NCT06331312Phase 3Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Polymyalgia Rheumatica
United States, Argentina, Australia, Belgium, Brazil +17 more
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.Active Not Recruiting
NCT05201066Phase 2Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Myelodysplastic Syndromes · Leukemia, Myelomonocytic, Chronic
United States, Australia, Brazil, Canada, China +10 more
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial HypercholesterolemiaRecruiting
NCT06597006Phase 3Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Familial Hypercholesterolemia - Homozygous
United States, Austria, China, Germany, Greece +6 more
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.Active Not Recruiting
NCT06247995Phase 1, Phase 2Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
United States, Australia, Canada, China, France +6 more
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.Active Not Recruiting
NCT06379217Phase 1Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Metastatic Neuroendocrine Prostate Cancer
United States, France, Germany, Spain, United Kingdom
A Study of 177Lu-FAP-2286 in Advanced Solid TumorsRecruiting
NCT04939610Phase 1, Phase 2Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Solid Tumor
United States, Australia, Canada, France, Italy +1 more
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant MelanomasActive Not Recruiting
NCT05415072Phase 1, Phase 2Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Metastatic Uveal Melanoma
United States, Australia, France, Germany, Netherlands +2 more
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)Active Not Recruiting
NCT05639114Phase 3Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Systemic Lupus Erythematosus
United States, Argentina, Brazil, Bulgaria, Canada +14 more
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular InterventionRecruiting
NCT06909565Phase 4Updated Jul 23, 2026
Sponsor: Duke University
Percutaneous Coronary Intervention · Peripheral Endovascular Intervention
United States
A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in KuwaitNot Yet Recruiting
NCT07454850N/AUpdated Jul 22, 2026
Sponsor: Novartis Pharmaceuticals
Leukemia, Myeloid, Chronic-Phase
HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With HypertensionRecruiting
NCT07644364Phase 1Updated Jul 22, 2026
Sponsor: Novartis Pharmaceuticals
Elevated Blood Pressure · Hypertension
Japan
A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf RegionNot Yet Recruiting
NCT07681258N/AUpdated Jul 22, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Myeloid Leukemia

5,058 studies found